Sign in

GCTK on Nasdaq

Glucotrack, Inc.

Glucotrack, Inc. is an American surgical and medical instruments and apparatus company.2 It is headquartered in Ashkelon, Israel.2 Its shares trade on Nasdaq under the symbol GCTK.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with FAMILY OFFICE OF AMERICA, INC., Bluejay Diagnostics, Inc. or QTREX Quantum Ltd., or pick any stock.

  • TickerGCTK on Nasdaq2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersAshkelon, Israel2
  • Incorporated inDE3
  • Business address301 Rt 17 North, Suite 800, Rutherford, Nj 070703
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300FJ98RZ4G4ULL572
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 48249172

See how the biggest companies compare on our leaderboards

Chief Executive Officer and intends to develop the technology to address the growing Type 1 and Type 2 diabetes market.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

1685.6%Operating margin5
1690.4%Net margin5
-$3.9MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2019

  • Research and development31¢$1.6M
  • Profit69¢$3.5M

Out of $208.0K in revenue.5

Financial statements

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Research and development expenses$9.8M$9.5M
General and administrative expenses$6.3M$5.0M
Total operating expenses$16.1M$14.5M
Loss from operations$16.1M$14.5M
Other (income) expense-$26.0K-$14.0K
Change in fair value of derivative liability$3.3M$798.0K
Loss on equity issuance$1.9M
Loss on settlement of liabilities$4.8M
Finance expense, net$57.0K$583.0K
Total other income$3.3M$8.1M
Net loss$19.4M$22.6M
Foreign currency translation adjustment-$49.0K-$24.0K
Comprehensive loss$19.3M$22.6M
Basic loss per share$31.22$4,106.00
Diluted loss per share$31.22$4,106.00
Weighted average number of common stock outstanding used in computing basic net loss per share621.1K shares5.5K shares
Weighted average number of common stock outstanding used in computing diluted net loss per share621.1K shares5.5K shares

Compare Glucotrack, Inc. with another company

Corporate structure

Glucotrack, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Glucotrack, Inc.

  • Glucotrack, Inc. Ashkelon, Israel

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Glucotrack, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$138.0K8 Dec 31, 2025$95.0K8 Dec 31, 2024+45.3%
Operating-lease assets (leased space)$33.0K8 Dec 31, 2025$59.0K8 Dec 31, 2024−44.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.4M8 Dec 31, 2025$5.6M8 Dec 31, 2024+31.4%

Properties, in its own words

The following table describes our principal property leased as of the date of this Annual Report. We believe the facility described below is adequate for our current needs.

Purpose · Location · Square Footage

The rest of Item 2

Office and Research Laboratory(1) · Front Royal, Virginia · 2,700

(1) · Monthly rental payments of $2,500 per month on a month-to-month basis. The lease expires on March 31, 2027.

Item 2 of the 10-K filed Mar 30, 2026.4

Leadership

Who has led Glucotrack, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Avner Gal2012–2015
  2. Paul Goode2024–now

Chair

  1. Avner Gal2012–2015

Chief financial officer

  1. Eran Hertz2014–2015
  2. Sami Sassoun2017
  3. James S. Cardwell2023
  4. Peter C. Wulff2025–now
201520202025
Board members and other officers (18)

Former names

  • Integrity Applications, Inc.Dec 27, 2010 to Dec 9, 20213

Timeline

  1. Oct 13, 20268-K Financial statements and exhibits34
  2. Sep 28, 20268-K Entered a material agreement35
  3. Sep 24, 20268-K Entered a material agreement; Regulation FD disclosure36
  4. Sep 23, 20268-K Regulation FD disclosure37
  5. Sep 18, 20268-K Executive or director change38
  6. Sep 14, 20268-K Entered a material agreement; Shareholder vote39
  7. Sep 11, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares40
  8. Sep 9, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares41
  9. Aug 28, 20268-K Completed an acquisition or sale42
  10. Aug 28, 20268-K Bylaws or fiscal year changed; Other events43
  11. Aug 27, 20268-K Regulation FD disclosure44
  12. Aug 19, 20268-K Shareholder vote45
  13. Apr 24, 2024New chief executive Paul Goode becomes CEO10
  14. Aug 24, 2012New chief executive Avner Gal becomes CEO11
  15. May 18, 2010Founded Glucotrack, Inc. is founded2

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202646

When it reported results

  1. May 14, 2026Reported quarterly or annual results47
  2. Mar 30, 2026Reported quarterly or annual results48
  3. Nov 13, 2025Reported quarterly or annual results49
  4. Aug 14, 2025Reported quarterly or annual results50
  5. May 14, 2025Reported quarterly or annual results51
  6. Mar 31, 2025Reported quarterly or annual results52

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

231 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 111 major events, 25 insider forms, 7 large holders, 1 private raises, 66 other. The latest 20:

  1. Oct 14, 2026S-1/A EDGAR
  2. Oct 13, 2026PRE 14A EDGAR
  3. Oct 13, 2026425 EDGAR
  4. Oct 13, 20268-K/A EDGAR
  5. Sep 28, 20268-K EDGAR
  6. Sep 24, 2026424B5 EDGAR
  7. Sep 24, 20268-K EDGAR
  8. Sep 23, 2026425 EDGAR
  9. Sep 23, 20268-K EDGAR
  10. Sep 18, 20268-K EDGAR
  11. Sep 18, 2026S-1 EDGAR
  12. Sep 14, 20268-K EDGAR
  13. Sep 11, 20268-K EDGAR
  14. Sep 9, 20268-K EDGAR
  15. Sep 2, 2026SCHEDULE 13G EDGAR
  16. Aug 28, 20268-K EDGAR
  17. Aug 28, 2026425 EDGAR
  18. Aug 28, 20268-K/A EDGAR
  19. Aug 27, 20268-K EDGAR
  20. Aug 21, 2026DEFA14A EDGAR

The 231 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 22, 2024SYCOFF DREWDirectorBuy182,540$1.26$230.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$500.0K 2024–2024
Money received by yearMoney received by year, 2024–2024: $500.0K in all. Private raises (Form D) $500.0K.$0$200K$400K$600K2024 · Private raises (Form D): $500.0K2024
Figures by year
YearPrivate raises (Form D)Total
2024$500.0K$500.0K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Apr 22, 2024Raised $500,000 in a private offering of equity58 Form D: 9 investors so far Form D

SEC filer profile

How Glucotrack, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGlucotrack, Inc.1
  • CIK0001506983
  • Employer ID (EIN)98-06689344
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address301 Rt 17 North, Suite 800, Rutherford, NJ 070701
  • Phone972 (8) 675-78781
  • Shares outstanding10,578,822 as of Aug 14, 20267
  • Public float$5.4M as of Jun 30, 20254
  • AuditorCBIZ CPAs P.C., Costa Mesa, California PCAOB ID 199; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceDec 27, 20101
  • Filings491 in all: 8-K (176), 10-Q (45), 4 (36), 3 (28), 10-K (15), DEF 14A (15), EFFECT (13), S-1/A (13)1
    All 44 form types

    424B3 (12), DEFA14A (12), CORRESP (11), PRE 14A (11), SC 13G (8), 8-K/A (7), D (7), S-1 (7), UPLOAD (7), NT 10-Q (6), POS AM (6), 424B5 (5), 10-K/A (4), 425 (4), S-8 (4), 4/A (3), ARS (3), D/A (3), NT 10-K (3), S-3 (3), SC 13G/A (3), SCHEDULE 13G (3), 10-Q/A (2), SC 13D (2), SCHEDULE 13G/A (2), SD (2), 3/A (1), 424B4 (1), 8-A12B (1), 8-A12G (1), CERT (1), DEFR14A (1), DRS (1), RW (1), S-3/A (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Aug 10, 2026
    Latest 8-K (8-K) Sep 28, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareGCTKThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Glucotrack, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 36 risks under these headings, as written.4

  • Risks Related to our Business and Industry
  • We have a history of operating losses, and there is no assurance that we will generate material revenues or become profitable in the near future.
  • When we evolve from a company primarily involved in development to a company also involved in commercialization, we may encounter difficulties in managing our growth and expanding our operations successfully.
  • We may have future capital needs and may not be able to obtain additional financing on acceptable terms.
  • Raising additional capital may cause dilution to our existing stockholders and investors, restrict our operations, or require us to relinquish rights to our products and/or product candidates on unfavorable terms to us.
  • Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.”
  • Economic crises and market instability may materially and adversely affect the demand for our products, as well as our ability to obtain credit or secure funds through sales of our stock, which may materially and adversely affect our business, financial condition and ability to fund our operations.
  • Glucotrack CBGM is not approved for sale in the United States or other jurisdictions.
  • We are highly dependent on the success of our primary product candidate, Glucotrack CBGM, and cannot give any assurance that it will receive regulatory approval or clearance or be successfully commercialized.
  • If our competitors develop and market products that are more effective, safer or less expensive than Glucotrack CBGM or our future product candidates, if any, our commercial opportunities will be adversely affected.
  • Our product development activities could be delayed or stopped.
  • The regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of Glucotrack CBGM or our future product candidates, if any.
The other 25 risks
  • Failure to recruit and enroll patients for clinical trials may cause the development of our product candidates to be delayed.
  • The terms of clearances or approvals and ongoing regulation of our products may limit how we manufacture and market our product candidates, which could materially impair our ability to generate anticipated revenues.
  • Even if we receive regulatory clearance or approval to market Glucotrack CBGM or our future product candidates, if any, the market may not be receptive to our products.
  • If the Glucotrack CBGM or our future product candidates, if any, fail to achieve sufficient reimbursement and coverage, we may not be able to generate significant revenue or achieve or sustain profitability.
  • We may not obtain insurance coverage to adequately cover all significant risk exposures.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities.
  • If we fail to attract and retain key management and scientific personnel, we may be unable to successfully develop or commercialize Glucotrack CBGM or our future product candidates, if any.
  • We rely on third parties to manufacture and supply our product.
  • Independent clinical investigators and contract research organizations that we may engage to conduct our clinical trials may not be diligent, careful or timely.
  • Our business may become subject to economic, political, regulatory and other risks associated with international operations, which could harm our business.
  • The funding that we received through the Israeli Innovation Authority (“IIA”) for research and development activities restricts our ability to manufacture products or to transfer technology outside of Israel of its first product which we have taken off the market and no longer have available for sale.
  • Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets.
  • Risks Related to Owning our Common Stock
  • We have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any dividends on our Common Stock in the foreseeable future.
  • If we are unable to continue to satisfy the applicable continued listing requirements of Nasdaq, our Common Stock could be delisted, and we and our stockholders could face significant material adverse consequences. In addition, Nasdaq has recently proposed a new $5 million market value of listed securities requirement that we may not satisfy and therefore could cause our Common Stock to be delisted by Nasdaq on an imminent basis, if approved by the SEC.
  • We had identified a material weakness in our internal control over financial reporting, and we may not be able to successfully implement remedial measures.
  • The market price and trading volume of our Common Stock has been volatile and may continue to be volatile due to numerous circumstances beyond our control, and stockholders could lose all or part of their investment.
  • We have a substantial number of convertible securities outstanding and the exercise of our outstanding warrants could have a dilutive effect on our Common Stock.
  • Our charter documents, Delaware law, and our commercial contracts may contain provisions that may discourage an acquisition of us by others and may prevent attempts by our stockholders to replace or remove our current management.
  • Risks Related to Intellectual Property
  • If we are unable to obtain and enforce patent protection for our products, our business could be materially harmed.
  • If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.
  • Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.
  • If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts.
  • Security threats to our information technology infrastructure could expose us to liability and damage our reputation and business.
  • If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and product could be significantly diminished.
  • We may be subject to claims that our employees or consultants have wrongfully used or disclosed alleged trade secrets.

Legal proceedings

We are not presently a party to any material litigation. From time to time, we may however, become involved in litigation matters arising in the ordinary course of our business.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58